NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free AVDL Stock Alerts $15.13 -0.12 (-0.79%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$14.95▼$15.6050-Day Range$14.87▼$18.8252-Week Range$9.50▼$19.09Volume624,421 shsAverage Volume1.16 million shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$24.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Avadel Pharmaceuticals alerts: Email Address Avadel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside59.7% Upside$24.17 Price TargetShort InterestBearish5.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.58) to $0.61 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.58 out of 5 starsMedical Sector689th out of 905 stocksPharmaceutical Preparations Industry325th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Avadel Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.91% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently increased by 18.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 2.8 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avadel Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for AVDL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.58) to $0.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 15.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avadel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More AVDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVDL Stock News HeadlinesMay 30, 2024 | globenewswire.comAvadel Pharmaceuticals to Present at Upcoming Investor ConferencesMay 22, 2024 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Shares New LUMRYZ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024May 22, 2024 | finance.yahoo.comAvadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024May 22, 2024 | globenewswire.comAvadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024May 21, 2024 | globenewswire.comAvadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of DirectorsMay 13, 2024 | msn.comAvadel gains for a second day as analysts see it prevailing in case vs Jazz/FDAMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market ExpansionMay 9, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comAvadel Pharmaceuticals GAAP EPS of -$0.30 misses by $0.29, revenue of $27.18M beats by $1.28MMay 8, 2024 | investorplace.comAVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | finance.yahoo.comAvadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...May 8, 2024 | globenewswire.comAvadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8April 29, 2024 | finance.yahoo.comWall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should KnowApril 25, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday TradingApril 21, 2024 | money.usnews.comAvadel Pharmaceuticals plcApril 16, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (AVDL)April 11, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near FutureApril 2, 2024 | seekingalpha.comAvadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly RevolutionApril 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceMarch 17, 2024 | finance.yahoo.comAVDL Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 25.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 10.000 putMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avadel Pharmaceuticals Amid Strong Q4 Performance and Promising Growth ProspectsSee More Headlines Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/07/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees154Year Founded2015Price Target and Rating Average Stock Price Target$24.17 High Stock Price Target$29.00 Low Stock Price Target$21.00 Potential Upside/Downside+59.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net Margins-284.42% Pretax Margin-284.11% Return on Equity-139.72% Return on Assets-79.53% Debt Debt-to-Equity RatioN/A Current Ratio2.85 Quick Ratio2.60 Sales & Book Value Annual Sales$27.96 million Price / Sales52.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book15.44Miscellaneous Outstanding Shares96,120,000Free Float92,274,000Market Cap$1.45 billion OptionableOptionable Beta1.75 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Gregory J. Divis Jr. (Age 57)CEO & Director Comp: $985.2kMr. Thomas S. McHugh (Age 59)Senior VP, Principal Financial and Accounting Officer & CFO Comp: $663.14kMr. Richard J. Kim (Age 55)Chief Commercial Officer Comp: $770.95kMr. Jerad G. SeurerGeneral Counsel & Company SecretaryMr. Gregory J. Davis (Age 59)VP of Corporate and Business Development Mr. Mark W. ElrodVice President of SalesMs. Angie WoodsVice President of People & CultureDr. Jordan S. Dubow M.D. (Age 45)Consultant Comp: $727.93kDr. Jason M. VaughnSenior Vice President of Technical OperationsMs. Jennifer Gudeman PharmDSenior Vice President of Medical & Clinical AffairsMore ExecutivesKey CompetitorsCollegium PharmaceuticalNASDAQ:COLLBicycle TherapeuticsNASDAQ:BCYCBioDelivery Sciences InternationalNASDAQ:BDSIImmunicNASDAQ:IMUXAeglea BioTherapeuticsNASDAQ:AGLEView All CompetitorsInsiders & InstitutionsCetera Investment AdvisersBought 113,978 shares on 5/24/2024Ownership: 0.119%Cetera Advisors LLCBought 7,531 shares on 5/24/2024Ownership: 0.096%Janus Henderson Group PLCBought 1,789,830 shares on 5/16/2024Ownership: 14.258%Kennedy Capital Management LLCBought 7,273 shares on 5/16/2024Ownership: 0.721%Gendell Jeffrey LBought 92,768 shares on 5/15/2024Ownership: 6.302%View All Insider TransactionsView All Institutional Transactions AVDL Stock Analysis - Frequently Asked Questions Should I buy or sell Avadel Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks. What is Avadel Pharmaceuticals' stock price target for 2024? 6 analysts have issued 1-year target prices for Avadel Pharmaceuticals' stock. Their AVDL share price targets range from $21.00 to $29.00. On average, they predict the company's share price to reach $24.17 in the next year. This suggests a possible upside of 59.7% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts. How have AVDL shares performed in 2024? Avadel Pharmaceuticals' stock was trading at $14.12 at the start of the year. Since then, AVDL stock has increased by 7.2% and is now trading at $15.13. View the best growth stocks for 2024 here. Are investors shorting Avadel Pharmaceuticals? Avadel Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 5,680,000 shares, an increase of 18.3% from the April 30th total of 4,800,000 shares. Based on an average daily volume of 1,250,000 shares, the days-to-cover ratio is currently 4.5 days. View Avadel Pharmaceuticals' Short Interest. When is Avadel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our AVDL earnings forecast. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.05. The business had revenue of $27.18 million for the quarter, compared to analyst estimates of $25.89 million. Avadel Pharmaceuticals had a negative trailing twelve-month return on equity of 139.72% and a negative net margin of 284.42%. The firm's revenue was up 2617.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.48) earnings per share. What ETFs hold Avadel Pharmaceuticals' stock? ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and AdvisorShares Dorsey Wright ADR ETF (AADR).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY). Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (14.26%), Gendell Jeffrey L (6.30%), Vivo Capital LLC (4.39%), Wealth Effects LLC (2.50%), Kennedy Capital Management LLC (0.72%) and Obermeyer Wood Investment Counsel Lllp (0.31%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVDL) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredSecret energy grid to power millions of homesThis high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type ...Porter & Company | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.